Novel Strategies for Managing Dyslipidemia: Treatment beyond Statins

References

• . Omran AR. The epidemiologic transition. A theory of the epidemiology of population change. Milbank Mem Fund Q. 1971;49(4):509–538
   PubMedGoogle Scholar
• . Mackenbach JP. The epidemiologic transition theory. J Epidemiol Comm Health. 1994;48(4):329–311
   Google Scholar
• . Moriyamal M. The change in mortality trend in the United States. Vital Health Stat 1. 1964;127:1–43
   Google Scholar
• . Dawber TR, Moore FE, Mann GV. Coronary heart disease in the Framingham study. Am J Public Health Nations Health. 1957;47(4 pt 2):4–24
   Google Scholar
• . Dawber TR, Meadors GF, Moore FE Jr. Epidemiological approaches to heart disease: the Framingham Study. Am J Public Health Nations Health. 1951;41(3):279–281
   PubMed Web of Science ®Google Scholar
• . Dawber TR, Kannel WB, Revotskie N, Stokes J 3rd, Kagan A, Gordon T. Some factors associated with the development of coronary heart disease: six years' follow-up experience in the Framingham study. Am J Public Health Nations Health. 1959;49:1349–1356
   PubMed Web of Science ®Google Scholar
• . Dawber TR, Kannel WB. Susceptibility to coronary heart disease. Mod Concepts Cardiovasc Dis. 1961;30:671–675
   PubMedGoogle Scholar
• . Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486–2497
   PubMed Web of Science ®Google Scholar
• . A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Report from the Committee of Principal Investigators. Br Heart J. 1978;40(10):1069–1118
   PubMedGoogle Scholar
• . Clofibrate and niacin in coaronary heart disease. JAMA. 1975;231(4):360–381
   PubMed Web of Science ®Google Scholar
• . Canner PL, Berge KG, Wenger NK, . Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol. 1986;8(6):1245–1255
   PubMed Web of Science ®Google Scholar
• . The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA. 1984;251(3):351–364
   PubMed Web of Science ®Google Scholar
• . Frick M, Elo O, Haapa K, . Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. JAMA. 1987;317(20):1237–1245
   Google Scholar
• . The treatment of cerebrovascular disease with Clofibrate. Final report of the Venterans Administration Cooperative Study of Atherosclerosis, Neurology Section. Stroke. 1973;4(4):684–693
   Google Scholar
• . Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation. 2000;102(1):21–27
   PubMed Web of Science ®Google Scholar
• . Meade T, Zuhrie R, Cook C, Cooper J. Bezafibrate in men with lower extremity arterial disease: randomised controlled trial. BMJ. 2002;325(7373):1139
   PubMed Web of Science ®Google Scholar
• . Rubins HB, Robins SJ, Collins D, . Gemfibrozil for the secondary prevention of coronary heart disease in me with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med. 1999;341(6):410–418
   PubMed Web of Science ®Google Scholar
• . Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344(8934):1383–1389
   PubMed Web of Science ®Google Scholar
• . Baigent C, Blackwell L, Emberson J, ; Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670–1681
   PubMed Web of Science ®Google Scholar
• . Collins R, Armitage J, Parish S, Sleight P, Peto R; Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003;361(9374):2005–2016
   PubMed Web of Science ®Google Scholar
• . Ridker PM, Danielson E, Fonseca FA, ; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195–2207
   PubMed Web of Science ®Google Scholar
• . Cannon CP, Braunwald E, McCabe CH, ; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350(15):1495–1504
   PubMed Web of Science ®Google Scholar
• . de Lemos JA, Blazing MA, Wiviott SD, ; A to Z Investigators. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA. 2004;292(11):1307–1316
   PubMed Web of Science ®Google Scholar
• . Pedersen TR, Faergeman O, Kastelein JJ, ; Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA. 2005;294(19):2437–2445
   PubMed Web of Science ®Google Scholar
• . Kjekshus J, Apetrei E, Barrios V, ; CORONA Group. Rosuvastatin in older patients with systolic heart failure. N Engl J Med. 2007;357(22):2248–2261
   PubMed Web of Science ®Google Scholar
• . Tavazzi L, Maggioni AP, Marchioli R, ; GISSI-HF Investigators. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, palcebo-controlled trial. Lancet. 2008;372(9645):1231–1239
   PubMed Web of Science ®Google Scholar
• . Wanner C, Krane V, März W, ; German Diabetes and Dialysis Study Investigators. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005;353(3):238–248
   PubMed Web of Science ®Google Scholar
• . Fellström BC, Jardine AG, Schnieder RE, ; AURORA Study Group. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360(14):1395–1407
   PubMed Web of Science ®Google Scholar
• . Holdaas H, Fellström B, Jardine AG, ; Assessment of LEscol in Renal Transplantation (ALERT) Study Investigators. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet. 2003;361(9374):2024–2031
   PubMed Web of Science ®Google Scholar
• . Sharp Collaborative Group. Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. Am Heart J. 2010;160(5):785–794
   PubMed Web of Science ®Google Scholar
• . Bates TR, Connaughton VM, Watts GF. Non-adherence to statin therapy: a major challenge for preventive cardiology. Expert Opin Pharmacother. 2009;10(18):2973–2985
   PubMed Web of Science ®Google Scholar
• . LaRosa JC, Grundy SM, Waters DD, ; Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352(14):1425–1435
   PubMed Web of Science ®Google Scholar
• . Barter P, Gotto AM, LaRosa JC, ; Treating to New Targets Investigators. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med. 2007;357(13):1301–1310
   PubMed Web of Science ®Google Scholar
• . Miller M, Cannon CS, Murphy SA, Qin J, Ray KK, Braunwald E; PROVE IT-TIMI 22 Investigators. Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol. 2008;51(7):724–730
   PubMed Web of Science ®Google Scholar
• . Culver AL, Ockene IS, Balasubramanian R, . Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative. Arch Intern Med. 2012;172(2):144–152
   PubMed Web of Science ®Google Scholar
• . www.FDA.gov. US Food and Drug Administration website. FDA expands advice on statin risks. http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm293330.htm#2. Updated August 9, 2012. Accessed May 25, 2012
   Google Scholar
• . Rossebø AB, Pedersen TR, Boman K, ; SEAS Investigators. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med. 2008;359(13):1343–1356
   PubMed Web of Science ®Google Scholar
• . Ginsberg HN, Elam MB, Lovato LC, ; ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362(17):1563–1574
   PubMed Web of Science ®Google Scholar
• . Boden WE, Probstfield JL, Anderson T, ; AIM-HIGH Investigators. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365(24):2255–2267
   PubMed Web of Science ®Google Scholar
• . Tall AR. Plalsma cholesteryl ester transfer protein. J Lipid Res. 1993;34(8):1255–1274
   PubMed Web of Science ®Google Scholar
• . Gurfinkel R, Joy TR. Anacetrapib: hope for CETP inhibitors? Cardiovasc Ther. 2011;29(5):327–339
   PubMed Web of Science ®Google Scholar
• . Barter PJ, Caulfield M, Eriksson M, ; ILLUMINATE Investigators. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357(21):2109–2122
   PubMed Web of Science ®Google Scholar
• . Forrest MJ, Bloomfield D, Briscoe RJ, . Torcetrapib-induced blood presure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone. Br J Pharmacol. 2008;154(7):1465–1473
   PubMed Web of Science ®Google Scholar
• . Fayad ZA, Mani V, Woodward M, ; dal-PLAQUE Investigators. Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial. Lancet. 2011;378(9802):1547–1559
   PubMed Web of Science ®Google Scholar
• . Lüscher TF, Taddei S, Kaski JC, ; dal-VESSEL Investigators. Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial. Eur Heart J. 2012;33(7):857–865
   PubMed Web of Science ®Google Scholar
• . Schwartz GG, Olsson AG, Ballantyne CM, ; dal-OUTCOMES Committees and Investigators. Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome. Am Heart J. 2009;158(6): 896–901
   Web of Science ®Google Scholar
• . Roche provides update on phase III study of dalcetrapib [media release]. Basel, Switzerland: Roche; May 7, 2012. http://www.roche.com/media/media_releases/med-cor-2012-05-07.htm. Accessed May 25, 2012
   Google Scholar
• . Nicholls SJ, Brewer HB, Kastelein JJ, . Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial. JAMA. 2011;306(19):2099–2109
   PubMed Web of Science ®Google Scholar
• . Bloomfield D, Carlson GL, Sapre A, . Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients. Am Heart J. 2009;157(2):352–360
   PubMed Web of Science ®Google Scholar
• . Cannon CP, Shah S, Dansky HM, ; Determining the Efficacy and Tolerability Investigators. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med. 2010;363(25):2406–2415
   PubMed Web of Science ®Google Scholar
• . www.ClinicalTrials.gov. REVEAL: Randomized Evaluation of the Effects of Anacetrapib Through Lipid-Modification. NCT01252953. http://clinicaltrials.gov/ct2/show/NCT01252953?term=NCT01252953&rank=1. Accessed May 25, 2012
   Google Scholar
• . Lambert G, Charlton F, Rye KA, Piper DE. Molecular basis of PCSK9 function. Atherosclerosis. 2009;203(1):1–7
   PubMed Web of Science ®Google Scholar
• . Lambert G, Sjouke B, Choque B, Kastelein JJ, Hovingh GK. The PCSK9 decade [published online ahead of print July 17, 2012]. J Lipid Res.
   Google Scholar
• . Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006;354(12):1264–1272
   PubMed Web of Science ®Google Scholar
• . Awan Z, Seidah NG, MacFadyen JG, . Rosuvastatin, proprotein convertase subtilisin/kexin type 9 concentrations, and LDL cholesterol response: the JUPITER trial. Clin Chem. 2012;58(1):183–189
   Web of Science ®Google Scholar
• . Abifadel M, Pakradouni J, Collin M, . Strategies for proprotein convertase subtilisin kexin 9 modulation: a perspective on recent patents. Expert Opin Ther Pat. 2010;20(11):1547–1571
   PubMed Web of Science ®Google Scholar
• . Dias C, Shaywitz A, Cooke B, . Effects of AMG 145, a fully human monoclonal antibody against pcsk9, on low-density lipoprotein cholesterol in subjects taking statins: a phase 1, randomized, double-blind, placebo-controlled, ascending multiple-dose study. J Am Coll Cardiol. 2012;59(13 s1):E1379–E1379
   Google Scholar
• . McKenney JM, Koren MJ, Kereiakes DJ, Hanotin C, Ferrand AC, Stein EA. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. J Am Coll Cardiol. 2012;59(25):2344–2353
   PubMed Web of Science ®Google Scholar
• . Stein EA, Gipe D, Bergeron J, . Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. Lancet. 2012;380(9836):29–36
   PubMed Web of Science ®Google Scholar
• . Agnello V, Abel G, Elfahal M, Knight GB, Zhang QX. Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. Proc Natl Acad Sci USA. 1999;96(22):12766–12771
   PubMed Web of Science ®Google Scholar
• . Balakumar P, Rose M, Ganti SS, Krishan P, Singh M. PPAR dual agonists: are they opening Pandora's Box? Pharmacol Res. 2007;56(2):91–98
   PubMed Web of Science ®Google Scholar
• . Henry RR, Lincoff AM, Mudaliar S, Rabbia M, Chognot C, Herz M. Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study. Lancet. 2009;374(9684): 126–135
   PubMed Web of Science ®Google Scholar
• . www.ClinicalTrials.gov. A Study with Aleglitazar in Patients with a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus. NCT01042769. http://clinicaltrials.gov/ct2/show/NCT01042769. Accessed May 25, 2012
   Google Scholar
• . Ito MK. ISIS 301012 gene therapy for hypercholesterolemia: sense, antisense, or nonsense? Ann Pharmacother. 2007;41(10):1669–1678
   PubMed Web of Science ®Google Scholar
• . Visser ME, Witztum JL, Stroes ES, Kastelein JJ. Antisense oligonucleotides for the treatment of dyslipidaemia. Eur Heart J. 2012;33(12):1451–1458
   PubMed Web of Science ®Google Scholar
• . Cuchel M, Bloedon LT, Szapary PO, . Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N Engl J Med. 2007;356(2): 148–156
   PubMed Web of Science ®Google Scholar
• . KYNAMRO (mipomersen sodium). Isis Pharmaceuticals, Inc. website. http://www.isip.com/Pipeline/Therapeutic-Areas/Cardiovascular.htm#Mipomersen. Accessed May 25, 2012
   Google Scholar
• . Raal FJ, Santos RD, Blom DJ, . Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;375(9719):998–1006
   PubMed Web of Science ®Google Scholar
• . US Food and Drug Administration; US Department of Health and Human Services. Briefing information for the October 18, 2012 meeting of the Endocrinologic and Metabolic Drugs Advisory Committee, http://www.fda.gov/advisorycommittees/committeesmeetingmaterials/drugs/endocrinologicandmetabolicdrugsadvisorycommittee/ucm323925.htm. Accessed December 6, 2012
   Google Scholar
• . Hussain MM, Shi J, Dreizen P. Microsomal triglyceride transfer protein and its role in apoB-lipoprotein assembly. J Lipid Res. 2003;44(1):22–32
   Google Scholar
• . Zamel RKhan R, Pollex RL, Hegele RA. Abetalipoproteinemia: two case reports and literature review. Orphanet J Rare Dis. 2008;3:19
   PubMed Web of Science ®Google Scholar
• . FDA grants orphan drug designation to aegerion pharmaceuticals' drug candidate, lomitapide, for treatment of familial chylomicronemia [press release]. Aegerion Pharmaceuticals, Inc.; March 15, 2011. http://ir.aegerion.com/releasedetail.cfm?releaseid=557106. Accessed May 25, 2012
   Google Scholar
• . Aegerion pharmaceuticals announces lomitapide 78-week phase III clinical data consistent with earlier results [press release]. Aegerion Pharmaceuticals, Inc.; January 6, 2012. http://ir.aegerion.com/releasedetail.cfm?ReleaseID=637610. Accessed May 25, 2012
   Google Scholar
• . Cuchel M, Meagher EA Marais AD, . L5 phase 3 study of microsomal triglyceride transfer protein inhibitor (MTP-i) lomitapide in subjects with homozygous familial hypercholesterolemia (HOFH): 56-week results. Atherosclerosis Supplements. 2010;11(2):14
   Google Scholar
• . US Food and Drug Administration; US Department of Health and Human Services. Briefing information for the October 17, 2012 meeting of the Endocrinologic and Metabolic Drugs Advisory Committee, http://www.fda.gov/advisorycommittees/committeesmeetingmaterials/drugs/endocrinologicandmetabolicdrugsadvisorycommittee/ucm323840.htm. Accessed December 6, 2012
   Google Scholar
• . Shin JJ, Osborne TF. Thyroid hormone regulation and cholesterol metabolism are connected through sterol regulatory element-binding protein-2 (SREBP-2). J Biol Chem. 2003;278(36):34114–34118
   PubMed Web of Science ®Google Scholar
• . Baxter JD, Webb P. Thyroid hormone mimetics: potential applications in atherosclerosis, obesity and type 2 diabetes. Nat Rev Drug Discov. 2009;8(4):308–320
   PubMed Web of Science ®Google Scholar
• . Grover GJ, Mellström K, Ye L, . Selective thyroid hormone receptor-beta activation: a strategy for reduction of weight, cholesterol, and lipoprotein (a) with reduced cardiovascular liability. Proc Natl Acad Sci USA. 2003;100(17):10067–10072
   PubMedGoogle Scholar
• . Ladenson PW, Kristensen JD, Ridgway EC, . Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia. N Engl J Med. 2010;362(10):906–916
   PubMed Web of Science ®Google Scholar
• . Karo Bio terminates the eprotirome program [press release]. Stockholm, Sweden: Karo Bio AB; February 14,2012. http://www.karobio.com/inves-tormedia/pressreleaser/pressrelease?pid=639535. Accessed May 25, 2012
   Google Scholar